Skip to main content


Fig. 6 | Arthritis Research & Therapy

Fig. 6

From: Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice

Fig. 6

Effects of Janus kinase (JAK) + spleen tyrosine kinase (SYK) inhibition on fibroblast-like synoviocytes and osteoclasts. a Cytokine and matrix metalloproteinase (MMP) production by fibroblast-like synoviocytes (FLS) from arthritic mice stimulated with 10 ng/ml rmTNF and 50 ng/ml rmIL-17A and treated in vitro with kinase inhibitors (0.5 μM) for 24 h. b Representative images after crystal violet staining and data showing the invasive potential of FLS from arthritic mice treated with kinase inhibitors (0.5 μM) in transwell collagen-coated chambers for 48 h. c Numbers of CD11bhiGr1cells, which contain most osteoclast precursors, and d rank ligand (RANKL) expression in spleens of DBA/1 mice immunized with glucose-6-phosphate isomerase + complete Freund’s adjuvant and exposed to JAK inhibitor (JAKi) + SYK inhibitor (SYKi) daily for a month. e Representative images after tartrate-resistant alkaline phosphatase staining showing the impact of JAKi/SYKi on osteoclast differentiation from bone marrow cells after 5 days in a RANKL + M-CSF enriched culture. f Activity of mature osteoclasts on cortical bone slices treated with kinase inhibitors (0.5 μM) for 48 h. Graphs show mean (+ standard error of the mean) of a representative experiment of 2–4 with 3–7 samples/group, *p <0.05 versus dimethyl sulfoxide (DMSO) or naive control. Veh vehicle

Back to article page